A．Surrogate endpoints are more reliable because they are based on objective measures.
B．Surrogate endpoints are not always reliable because the disease being treated may be too complicated to gauge with just one tool.
C．Surrogate endpoints may help streamline the process of drug approval.
D．Surrogate endpoints do not always reflect the safety of a drug because it may have many more effects than the one being measured.